| HOME >> BIOLOGY >> TECHNOLOGY |
Total current liabilities 2,468,077 1,853,070
Long-term liabilities, less current
portion:
Unsecured loans payable 1,531,129 1,472,717
Bank notes payable 18,243 1,351
Long-term convertible notes payable 2,120,562 2,365,962
Less: discount relating to warrants (958,312) (1,371,446)
Long-term convertible notes payable -
net 1,162,250 994,516
Total long-term liabilities 2,711,622 2,468,584
Minority interest in a subsidiary 110,278 103,362
Shareholders' equity (deficiency)
Common stock - $0.001 par value
Authorized 200,000,000 shares at
September 30, 2007 and December 31,
2006 respectively. Issued and
outstanding 76,847,710 and
70,149,556 shares at September 30,
2007 and December 31, 2006,
respectively 76,848 70,150
Preferred stock - $0.001 par value
Authorized 20,000,000 shares, nil
shares issued and outstanding at
September 30, 2007 and December 31,
2006, respectively -- --
Additional paid-in capital 8,844,813 8,311,975
Stock-based compensation reserve (348,198) (523,468)
Deficit accumulated (10,311,326) (7,766,654)
Accumulated other comprehensive
income 6,418 1,166
Total shareholders' equity
(deficiency) (1,731,445) 93,169
Total liabilities and stockholders'
equity $3,558,532
'/>"/>
| SOURCE Kiwa Bio-Tech Products Group Corporation Copyright©2007 PR Newswire. All rights reserved |